Revvity Inc (RVTY)
被高估基本面
54
价格
$152.91
市值
$16.85B
第一部分 · 这家公司值多少
概览
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$2.91B
最近12个月（截至2026/7/5）
净利润
$238M
最近12个月（截至2026/7/5）
自由现金流
$509M
股东权益合计
$7.25B
负债合计
$4.92B
流动比率
1.80
利息覆盖率
3.82
债务/EBITDA
4.39
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$95.90
当前价格
$152.91
安全边际
-59.4%
公允价值区间
$62.34 - $129.47
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
73.15
ROE
3.3%
市净率（P/B）
2.36
P/FCF
30.57
毛利率
-
ROIC
2.6%
盈利能力雷达图
价值创造（经济护城河）
ROIC
2.6%
WACC
9.2%
ROIC − WACC
-6.6 pp
ROIC 低于资本成本：公司每投入一美元都在毁灭价值。
基本面分析标准
通过（16）
- EPS shows upward trend
- Price CAGR 9.08%
- P/B Ratio 2.36
- Debt/Equity ratio
- Operating Margin 12.3%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Analyst Consensus 52% Buy
- Earnings Surprise avg 6.1%
- Earnings Quality (OCF/NI) 2.64
- Share Dilution -5.2%
- Piotroski F-Score 5/9
未通过（9）
- EPS CAGR 3.96%
- ROIC 2.6%
- P/FCF 30.57
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.3%
- Revenue Growth 5Y -5.5%
- Net Margin Trend 8.2% vs 10.2%
不可用（3）
- Gross Margin NaN%
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-评分
信号混杂：部分领域需关注
盈利质量
高质量：盈利有现金流支撑
股权稀释
正在回购股份，对股东友好
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Dr. Prahlad R. Singh Ph.D. | CEO, President & Director | 60 |
| Mr. Maxwell Krakowiak | Senior VP & CFO | 35 |
| Mr. Tajinder S. Vohra | Senior Vice President of Global Operations | 59 |
| Mr. Joel S. Goldberg | Senior VP of Administration, General Counsel & Secretary | 56 |
| Ms. Miriame Victor | Senior Vice President & Chief Business Officer | 44 |
| Ms. Anita Gonzales | Chief Accounting Officer, VP & Controller | 49 |
| Mr. Bryan A. Kipp | Senior VP of Technology & Licensing | - |
| Dr. Madhuri Hegde FACMG, Ph.D. | Senior VP & Chief Scientific Officer | - |
| Mr. Stephen Barr Willoughby | Senior VP of Investor Relations & Head of ESG | - |
| Ms. Magali Four | Senior VP and Chief People & Culture Officer | - |
审计风险
9
董事会风险
2
薪酬风险
8
股东权利风险
4
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for RVTY, sourced from Markets Gazette.